Home › NDC Lookup › RxCUI directory › RxCUI 2701409

Crinecerfont 50 MG/ML Oral Solution — RxCUI 2701409

Name: Crinecerfont 50 MG/ML Oral Solution (RxCUI 2701409)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic clinical drug

RxCUI 2701409 Semantic clinical drug · SCD ● Current RxNorm concept 4 FDA products 4 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2701409

Official nameCrinecerfont 50 MG/ML Oral Solution

Concept typeSemantic clinical drug (SCD)

RxNorm statusCurrent RxNorm concept

FDA products mapped4

Package NDCs mapped4

Reported Medicaid activity (SDUD)1,257 prescriptions · 14 state & territory Medicaid programs · latest period Q4 2025

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

🕸️ Concept Web — How Crinecerfont 50 MG/ML Oral Solution Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept Crinecerfont 50 MG/ML Oral Solution RxCUI 2701409 Semantic clinical drug · SCD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 1

The active substance itself — no strength, form, or brand attached yet.
- Crinecerfont 2701386 IN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Crenessity 2701392 BN
Dose forms 9

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Crinecerfont Oral Solution 2701408 SCDF
- Crinecerfont Oral Liquid Product 2701407 SCDG
- Crinecerfont Oral Product 2701388 SCDG
- Crinecerfont Oral Solution [Crenessity] 2701412 SBDF
- Crenessity Oral Liquid Product 2701411 SBDG
- Crenessity Oral Product 2701394 SBDG
- Oral Solution 316968 DF
- Oral Liquid Product 1151137 DFG
- +1 more in this family
Clinical & branded drugs 3

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- Crinecerfont 50 MG/ML 2701406 SCDC
- Crinecerfont 50 MG/ML Oral Solution [Crenessity] 2701413 SBD
- Crinecerfont 50 MG/ML [Crenessity] 2701410 SBDC

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Crinecerfont 50 MG/ML SCDC · 2701406
Crinecerfont Oral Solution SCDF · 2701408
Crinecerfont Oral Liquid Product SCDG · 2701407
Crinecerfont Oral Product SCDG · 2701388

Brand-Name Concepts

Crinecerfont 50 MG/ML Oral Solution [Crenessity] SBD · 2701413
Crinecerfont 50 MG/ML [Crenessity] SBDC · 2701410
Crinecerfont Oral Solution [Crenessity] SBDF · 2701412
Crenessity Oral Liquid Product SBDG · 2701411
Crenessity Oral Product SBDG · 2701394
Crenessity BN · 2701392

📦 FDA Products & Package NDCs

4 products · 4 package NDCs

4 package NDCs map to RxCUI 2701409 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
70370-5025-01	60 CAPSULE in 1 BOTTLE (70370-5025-1)	Crenessity	Neurocrine Biosciences, Inc.	2024-12-13
70370-5050-01	60 CAPSULE in 1 BOTTLE (70370-5050-1)	Crenessity	Neurocrine Biosciences, Inc.	2024-12-13
70370-5100-01	30 CAPSULE in 1 BOTTLE (70370-5100-1)	Crenessity	Neurocrine Biosciences, Inc.	2024-12-13
70370-5250-01	30 mL in 1 BOTTLE (70370-5250-1)	Crenessity	Neurocrine Biosciences, Inc.	2024-12-13

Observed labelers: Neurocrine Biosciences, Inc. (4) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.